I期临床试验-话题@MedSci

#I期临床试验#

226篇内容 | 1878人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2088678, encodeId=958f20886e889, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, objectType=article, longId=56014, objectId=262d56014f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262d56014f0, replyNumber=0, likeNumber=34, createdTime=2015-10-04, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262d56014f0, moduleTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=262d56014f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088682, encodeId=4f5c208868275, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）, objectType=article, longId=70373, objectId=0c80e0373e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c80e0373e2, replyNumber=0, likeNumber=27, createdTime=2017-04-28, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c80e0373e2, moduleTitle=ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c80e0373e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088676, encodeId=d0af20886e68d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段, objectType=article, longId=55622, objectId=6995556228c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6995556228c, replyNumber=0, likeNumber=28, createdTime=2015-09-05, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6995556228c, moduleTitle=第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6995556228c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088680, encodeId=0860208868048, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验, objectType=article, longId=56022, objectId=21385602249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21385602249, replyNumber=0, likeNumber=0, createdTime=2016-06-05, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21385602249, moduleTitle=招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21385602249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088681, encodeId=63b22088681e5, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=FDA送大复方中药连花清瘟的圣诞礼物，在美国开展II期临床试验, objectType=article, longId=61125, objectId=30726112531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30726112531, replyNumber=0, likeNumber=40, createdTime=2016-04-29, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30726112531, moduleTitle=FDA送大复方中药连花清瘟的圣诞礼物，在美国开展II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30726112531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088673, encodeId=5f5e20886e316, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Clin Cancer Res：PI3K靶向新药Pictilisib在进展期实体肿瘤病人中的I期临床试验, objectType=article, longId=42400, objectId=3e374240092, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e374240092, replyNumber=0, likeNumber=32, createdTime=2014-12-08, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e374240092, moduleTitle=Clin Cancer Res：PI3K靶向新药Pictilisib在进展期实体肿瘤病人中的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e374240092)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088679, encodeId=46aa20886e980, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验, objectType=article, longId=56018, objectId=86745601843, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86745601843, replyNumber=0, likeNumber=22, createdTime=2016-07-27, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86745601843, moduleTitle=招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86745601843)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088675, encodeId=fd7f20886e5ba, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Lancet子刊：2型糖尿病新药trelagliptin III期临床试验结果乐观, objectType=article, longId=45947, objectId=66654594e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66654594e34, replyNumber=0, likeNumber=24, createdTime=2015-10-15, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66654594e34, moduleTitle=Lancet子刊：2型糖尿病新药trelagliptin III期临床试验结果乐观, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66654594e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088669, encodeId=e34a2088669c9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验, objectType=article, longId=37047, objectId=6eb73e0471c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6eb73e0471c, replyNumber=0, likeNumber=28, createdTime=2015-04-12, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6eb73e0471c, moduleTitle=Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eb73e0471c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088670, encodeId=478720886e0a5, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果, objectType=article, longId=37049, objectId=a8b93e049a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b93e049a1, replyNumber=0, likeNumber=47, createdTime=2014-08-10, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b93e049a1, moduleTitle=Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b93e049a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088667, encodeId=0611208866e17, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=ASCO 2014：索凡替尼的研磨制剂治疗晚期实体瘤的Ⅰ期临床试验, objectType=article, longId=35686, objectId=283d3568632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=283d3568632, replyNumber=0, likeNumber=41, createdTime=2015-02-17, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=283d3568632, moduleTitle=ASCO 2014：索凡替尼的研磨制剂治疗晚期实体瘤的Ⅰ期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=283d3568632)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088671, encodeId=0c5120886e131, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=汤森路透：五个进入III期临床试验的更具前景药物品种, objectType=article, longId=40850, objectId=966c408506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=966c408506a, replyNumber=0, likeNumber=38, createdTime=2014-10-13, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=966c408506a, moduleTitle=汤森路透：五个进入III期临床试验的更具前景药物品种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=966c408506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088665, encodeId=70032088665b9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=ASCO 2014：贝伐单抗加化疗用于直肠癌术前治疗的II期临床试验, objectType=article, longId=35259, objectId=6fa835259a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fa835259a8, replyNumber=0, likeNumber=30, createdTime=2014-07-21, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fa835259a8, moduleTitle=ASCO 2014：贝伐单抗加化疗用于直肠癌术前治疗的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fa835259a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088674, encodeId=822820886e411, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想, objectType=article, longId=45906, objectId=c85f4590698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c85f4590698, replyNumber=0, likeNumber=32, createdTime=2015-08-21, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c85f4590698, moduleTitle=Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c85f4590698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088668, encodeId=0ac9208866807, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=BMJ：新型抗结核三联方案PaMZ III期临床试验即将启动, objectType=article, longId=36188, objectId=2cdb361889b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cdb361889b, replyNumber=0, likeNumber=39, createdTime=2014-09-19, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cdb361889b, moduleTitle=BMJ：新型抗结核三联方案PaMZ III期临床试验即将启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cdb361889b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088672, encodeId=847220886e2fa, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=汤森路透：五个进入II期临床试验的更具前景药物品种, objectType=article, longId=41019, objectId=db344101960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db344101960, replyNumber=0, likeNumber=48, createdTime=2015-04-19, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db344101960, moduleTitle=汤森路透：五个进入II期临床试验的更具前景药物品种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db344101960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088664, encodeId=892420886649a, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=NEJM：阿尔茨海默病新药Solanezumab III期临床试验失败, objectType=article, longId=30355, objectId=46a930355d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46a930355d0, replyNumber=0, likeNumber=41, createdTime=2014-10-26, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46a930355d0, moduleTitle=NEJM：阿尔茨海默病新药Solanezumab III期临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46a930355d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088666, encodeId=73b5208866614, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=ASCO 2014：MSC2156119J+吉非替尼治疗MET阳性EGFR突变晚期NSCLC的I/II期临床试验, objectType=article, longId=35667, objectId=f1cf3566e12, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1cf3566e12, replyNumber=0, likeNumber=40, createdTime=2014-12-07, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1cf3566e12, moduleTitle=ASCO 2014：MSC2156119J+吉非替尼治疗MET阳性EGFR突变晚期NSCLC的I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1cf3566e12)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088662, encodeId=3885208866255, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=阿斯利康旗下三个靶向肿瘤药物进入III期临床试验, objectType=article, longId=19185, objectId=10d619185bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10d619185bd, replyNumber=0, likeNumber=0, createdTime=2014-01-06, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10d619185bd, moduleTitle=阿斯利康旗下三个靶向肿瘤药物进入III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10d619185bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088661, encodeId=bb3a2088661a6, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=H5N1流感疫苗Ⅰ期临床试验效果已超既定标准, objectType=article, longId=17697, objectId=bf691e6976d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf691e6976d, replyNumber=0, likeNumber=42, createdTime=2013-05-15, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf691e6976d, moduleTitle=H5N1流感疫苗Ⅰ期临床试验效果已超既定标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf691e6976d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床试验

2020-05-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验

2015-10-04

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）

2017-04-28

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段

2015-09-05

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

招募患者：比较MSC2156119J联合吉非替尼与化疗治疗EGFR突变的MET阳性晚期NSCLC患者的Ib及II期临床试验

2016-06-05

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

FDA送大复方中药连花清瘟的圣诞礼物，在美国开展II期临床试验

2016-04-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Clin Cancer Res：PI3K靶向新药Pictilisib在进展期实体肿瘤病人中的I期临床试验

2014-12-08

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

招募患者：西妥昔单抗联合化疗对比单纯化疗一线治疗晚期头颈部鳞癌的疗效和安全性的III期临床试验

2016-07-27

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Lancet子刊：2型糖尿病新药trelagliptin III期临床试验结果乐观

2015-10-15

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验

2015-04-12

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果

2014-08-10

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

ASCO 2014：索凡替尼的研磨制剂治疗晚期实体瘤的Ⅰ期临床试验

2015-02-17

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

汤森路透：五个进入III期临床试验的更具前景药物品种

2014-10-13

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

ASCO 2014：贝伐单抗加化疗用于直肠癌术前治疗的II期临床试验

2014-07-21

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想

2015-08-21

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

BMJ：新型抗结核三联方案PaMZ III期临床试验即将启动

2014-09-19

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

汤森路透：五个进入II期临床试验的更具前景药物品种

2015-04-19

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

NEJM：阿尔茨海默病新药Solanezumab III期临床试验失败

2014-10-26

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

ASCO 2014：MSC2156119J+吉非替尼治疗MET阳性EGFR突变晚期NSCLC的I/II期临床试验

2014-12-07

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

阿斯利康旗下三个靶向肿瘤药物进入III期临床试验

2014-01-06

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

H5N1流感疫苗Ⅰ期临床试验效果已超既定标准

2013-05-15

科室
- - 订阅+
  - 更多科室
工具
服务